Table 1.
Monoclonal antibodies investigated in Phase I clinical trials of pancreatic cancer.
| Target molecule | Antibody | Drugs in combined therapy | Ref. |
|---|---|---|---|
| EGFR | Cetuximab | Bortezomib | [124] |
| Erlotinib + bevacizumab | [125] | ||
| Gemcitabine + radiation | [17,126] | ||
| ABX-EGFR | Panitumumab | [23] | |
| HER2 | Trastuzumab | Tipifarnib | [33] |
| IL-12 | [35] | ||
| VEGF | Bevacizumab | Sorafenib | [127,128] |
| RAAG12 | RAV 12 | [129] | |
| MUC1 | HuPAM 4 | Y-90 radiolabeled | [89] |
| Glucoprotein with mucin properties | CC49 | Radioisotope conjugated to mAb | [130] |
| CanAg | HuC242-DM4 | Maytansinoid DM4 conjugated mAb | [131] |
| Mesothelin | MORAb-009 | [70] | |
| SS1(dsFv) PE38 | Immunotoxin conjugated | [69] | |
| Lewis Y | LMB-9 | Immunotoxin conjugated | [118] |
EGFR: EGF receptor; mAb: Monoclonal antibody; MUC: Mucin.